Author: Dilbade yildiz Ekinci (Turkey)
Co-authors: Adem Ugurlu
Purpose
To compare aggressive posterior retinopathy of prematurity (AP-ROP) with type-1 retinopathy of prematurity (ROP) with regarding risk factors, complications and treatment outcomes.
Setting/Venue
The study was conducted as two centered and retrospective design between July 2018-February 2021 in Diyarbakir Gazi Yasargil Training and Research Hospital Department of Ophthalmology, Turkey and Erzincan Binali Yildirim University Faculty of Medicine Department of Ophthalmology, Turkey.
Methods
Data of 6916 eyes of 3458 infants were evaluated and recorded. Examination findings were recorded according to the Classification of Retinopathy of Prematurity guideline. The following informations were recorded: gestational age, birth weight, type of delivery, duration of staying in neonatal intensive care unit (NICU) and oxygen therapy, age at the time of diagnosis and treatment (weeks), the location and type of ROP, the severity of ROP, vascular characteristics of ROP, treatment status, postmenstrual age, treatment modality, and retinal vascular development.
Results
Eight hundred eighty nine (25.7%) of 3458 babies were diagnosed with ROP. Two hundred forty eyes of 127 (3.7%) infants were treated for ROP (intravitreal anti VEGF (IVA) or laser photocoagulation (LPC) treatment). Sixty six eyes were AP-ROP and 174 eyes were type-1 ROP in the study. There was no significant difference in gestational age, birth weight, type of delivery, duration of staying in NICU and oxygen therapy between two groups. Sixty six eyes were treated with IVA therapy in AP-ROP group. In infants with type-1 ROP, 96 eyes were treated with IVA and 78 eyes were treated with LPC. ROP recurrence occured in 18 eyes which 8 were treated with IVA and 7 were treated with LPC and 3 were treated with LPC + surgical intervention (pars plana vitrectomy) in AP-ROP group, while 2 eyes which were treated with LPC in type-1 ROP group.
Conlusions
Recurrence and retreatment (IVA, LPC and surgical intervention) are more frequent in AP-ROP than type-1 ROP even when treated with IVA and LPC.
Financial Disclosure
The authors declare no financial disclosure and conflicts of interest in the study.
Comments
-
